Mandanas buys Energy Vault (NRGV) shares worth $20,520
Investing.com - Craig-Hallum initiated coverage on Dyadic International (NASDAQ:DYAI) with a Buy rating and a $5.00 price target on Monday. The target represents significant upside potential from the current stock price of $0.92, with analysts setting an even more optimistic high target of $9.00.
The research firm cited Dyadic’s recent strategic shift toward commercializing its proprietary C1-cell protein production platform and Dapibus platforms after four decades focused primarily on research and development.
Craig-Hallum noted that Dyadic had previously concentrated on utilizing its technology to help create vaccines faster and more cost efficiently, but has now pivoted toward commercial applications.
The firm indicated this strategic shift is "already bearing fruit" for the biotechnology company, according to its research note released Monday morning.
Craig-Hallum projects that Dyadic’s new commercial focus could put the company on track to achieve $100 million in revenues and "meaningful profits" over the next five years.
In other recent news, Dyadic International Inc. reported its financial results for the second quarter of 2025, highlighting a notable increase in revenue. The company achieved a revenue of $967,000, slightly surpassing analysts’ expectations, although it continued to report a net loss with an EPS of -0.06, which was in line with forecasts. Despite the revenue growth, the ongoing losses have raised concerns among investors about the company’s future profitability. There were no significant mergers or acquisitions reported for Dyadic International Inc. during this period. Additionally, no analyst upgrades or downgrades were noted in the recent reports. These recent developments provide insight into Dyadic’s current financial position and investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.